Washington University School of Medicine
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Washington University School of Medicine
With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?
Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
- Academic and Research Institutions